Evidence map›Paper›PMID 36451062›Full record

ArticleMolecular biotechnology2023

Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing.

Fatma Gizem Sonugür, Cansu Babahan, Samira Abdi Abgarmi, Hakan Akbulut

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05526183 (Phase I Randomized Double-Blind Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine in Healthy Volunteers Aged 18-45 Years), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05526183 phase1unknown statusnot on this map

Phase I Randomized Double-Blind Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine in Healthy Volunteers Aged 18-45 Years

TypeinterventionalSponsorAnkara City Hospital BilkentRan2022 to 2023Enrolled36ConditionsCOVID-19ArmsAdeno-viral vector vaccine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fatma Gizem SonugürDepartment of Tumor Biology, Cancer Research Institute, Ankara University, Ankara, Turkey.
Cansu BabahanDepartment of Tumor Biology, Cancer Research Institute, Ankara University, Ankara, Turkey.
Samira Abdi AbgarmiDepartment of Tumor Biology, Cancer Research Institute, Ankara University, Ankara, Turkey.
Hakan AkbulutDepartment of Tumor Biology, Cancer Research Institute, Ankara University, Ankara, Turkey. akbulut@medicine.ankara.edu.tr.ORCID http://orcid.org/0000-0003-1631-5739
Ankara University · TR

Funding

Türkiye Bilimsel ve Teknolojik Araştırma Kurumu TUBITAK-1004-18AG020
6 · The paper itself

Abstract

Adenoviral vectors (AV) are commonly used as vaccine and gene therapy vehicles because of their ease of construction, ability to grow to high titers in the large-scale production process, and safety for human applications. However, the efficiency rate of downstream processes for adenoviral vectors still varies greatly. In the current study, we aimed to investigate the effect of the downstream treatment protocol and microfiltration of the harvested upstream material on viral vector yield. We compared the performance of the repeated freeze-thaw (RFT) and the Tween-20 detergent lysis (DLT) methods. In addition, the effects of the cell lysis method, incubation temperature, and time on viral yield were investigated. The samples were incubated at either room temperature or 37 °C for 1-, 2-, and 4-h periods. Samples were filtered with PES and SFCA membrane. Virus yield and infectivity were assayed by qPCR and immuno-titration. In conclusion, our results suggest that 2-h incubation gives the best results when incubated at 37 °C for denarase activity when Tween-20 is used for virus recovery. If the room temperature is preferred, 4-h incubation could be preferred. A phase 1 clinical trial (NCT05526183, January 21, 2022) was started with the recombinant adenovirus used in the study.

Indexed as

Genetic VectorsPolysorbatesAdenoviridaeGenetic TherapyHumansTemperaturePolysorbatesBioprocess developmentDownstream processingSARS-CoV-2VaccinesViruses

Identifiers

PMID36451062
PMCPMC9713150
OpenAlexW4310483863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.